IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
03 Dicembre 2024 - 2:30PM
Business Wire
The Company to host an earnings conference call
via webcast
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA), an AI-driven biotherapeutic research and technology
company, today announced that it will host a conference call to
discuss its quarterly results and recent business highlights for
second quarter fiscal year 2025, on Tuesday, December 10, 2024, at
10:30 am Eastern Time. The financial results will be issued in a
press release prior to the call. ImmunoPrecise management will host
the conference call followed by a question-and-answer period.
Conference Call and Webcast Details
The Company will host a live conference call and webcast to
discuss these results and provide a corporate update on Tuesday,
December 10, 2024, at 10:30AM ET.
The conference call will be webcast live and available for
replay via a link provided in the Events section of the Company’s
IR pages at
https://ir.ipatherapeutics.com/events-and-presentations/default.aspx.
***Participant Dial-In Details***
Participants call one of the allocated dial-in numbers (below)
and advise the Operator of either the Conference ID 3224490 or
Conference Name.
USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800)
715-9871 Canada - Toronto (647) 932-3411 Canada - Toll-Free (800)
715-9871
***Webcast Details***
Attendee URL: https://events.q4inc.com/attendee/560160139
Please call the conference telephone number five minutes prior
to the start time. An operator will register your name and
organization.
Anyone listening to the call is encouraged to read the company's
periodic reports available on the company’s profile at
www.sedarplus.com and www.sec.gov, including the discussion of risk
factors and historical results of operations and financial
condition in those reports.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that
leverages multi-omics modeling and complex artificial intelligence
through a series of proprietary and patented technologies. The
Company owns an integrated end-to-end suite of capabilities to
support the development of therapeutic antibodies and are known for
solving very complex industry challenges. IPA has several
subsidiaries in North America and Europe including entities such as
Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies
(Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V.
(collectively, the “IPA Family”).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241203734695/en/
Investor Relations Contact
investors@ipatherapeutics.com
Grafico Azioni ImmunoPrecise Antibodies (NASDAQ:IPA)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni ImmunoPrecise Antibodies (NASDAQ:IPA)
Storico
Da Gen 2024 a Gen 2025